The rise and fall of insulin secretion in type 1 diabetes mellitus

Diabetologia

Volumn 49, Issue 2, 2006, Pages 261-270

  Tsai, E B ^a   Sherry, N A ^a   Palmer, J P ^b   Herold, K C ^a,c  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Autoimmunity; C peptide; Insulin secretion; Natural history; Type 1 diabetes

Indexed keywords

C PEPTIDE; INSULIN;

AUTOIMMUNE DISEASE; CELL DAMAGE; CLINICAL FEATURE; DIABETIC PATIENT; DISEASE COURSE; DISEASE DURATION; DISEASE MODEL; GROWTH; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESPONSE; MEAL; METABOLISM; PANCREAS ISLET BETA CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW;

ADOLESCENT; ADULT; AGING; AUTOIMMUNITY; BODY MASS INDEX; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; INSULIN-SECRETING CELLS; PREDIABETIC STATE;

EID: 31844443761     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-0100-8     Document Type: Review

References (59)

1. Keymeulen B, Vandemeulebroucke E, Ziegler et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598-2608
2. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR (2001) Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358:1749-1753
3. Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698
4. Herold KC, Gitelman SE, Masharani U et al (2005) A single course of anti-CD3 monoclonal antibody hOKT3 {gamma} 1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes 54:1763-1769
5. Diabetes Prevention Trial - Type 1 Diabetes Study Group (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685-1691
6. Skyler JS, Krischer JP, Wolfsdorf J et al (2005) Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 28:1068-1076
7. Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP (1998) Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 47:324-330
8. Polonsky K, Frank B, Pugh W et al (1986) The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes 35:379-386
9. Polonsky KS, Licinio-Paixao J, Given BD et al (1986) Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77:98-105
10. Polonsky KS, Given BD, Hirsch L et al (1988) Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81:435-441
11. Polonsky KS, Given BD, Hirsch LJ et al (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231-1239
12. Steele C, Hagopian WA, Gitelman S et al (2004) Insulin secretion in type 1 diabetes. Diabetes 53:426-433
13. Bonner-Weir S (2000) Islet growth and development in the adult. J Mol Endocrin 24:297-302
14. Scaglia L, Cahill CJ, Finegood DT, Bonner-Weir S (1997) Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 138:1736-1741
15. Bouwens L, Rooman I (2005) Regulation of pancreatic beta cell mass. Physiol Rev 85:1255-1270
16. Finegood DT, Scaglia L, Bonner-Weir S (1995) (Perspective) Dynamics of β-cell mass in the growing rat pancreas: estimation with a simple mathematical model. Diabetes 44:249-256
17. Caprio S, Plewe G, Diamond MP et al (1989) Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 114:963-967
18. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV (1986) Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 315:215-219
19. Saad RJ, Keenan BS, Danadian K, Lewy VD, Arslanian SA (2001) Dihydrotestosterone treatment in adolescents with delayed puberty: does it explain insulin resistance of puberty? J Clin Endocrinol Metab 86:4881-4886
20. Goran MI, Gower BA (2001) Longitudinal study on pubertal insulin resistance. Diabetes 50:2444-2450
21. Bloch CA, Clemons P, Sperling MA (1987) Puberty decreases insulin sensitivity. J Pediatr 110:481-487
22. Cook JS, Hoffman RP, Stene MA, Hansen JR (1993) Effects of maturational stage on insulin sensitivity during puberty. J Clin Endocrinol Metab 77:725-730
23. Brandou F, Brun JF, Mercier J (2005) Limited accuracy of surrogates of insulin resistance during puberty in obese and lean children at risk for altered glucoregulation. J Clin Endocrinol Metab 90:761-767
24. Moran A, Jacobs DR Jr, Steinberger J et al (1999) Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 48:2039-2044
25. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV (1991) Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 72:277-282
26. Arslanian S, Suprasongsin C, Janosky JE (1997) Insulin secretion and sensitivity in black versus white prepubertal healthy children. J Clin Endocrinol Metab 82:1923-1927
27. Schatz D, Cuthbertson D, Atkinson M et al (2004) Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus - a new surrogate measure of non-progression? Pediatr Diabetes 5:72-79
28. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR (1997) Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88:561-572
29. Pick A, Clark J, Kubstrup C, Pugh W, Bonner-Weir S, Polonsky K (1998) Role of apoptosis in failure of β cell mass compensation for insulin resistance and β cell defects in the male Zucker diabetic fatty (ZDF) rat. Diabetes 47:358-364
30. Montana E, Bonner-Weir S, Weir GC (1994) Transplanted beta cell response to increased metabolic demand. Changes in beta cell replication and mass. J Clin Invest 93:1577-1582
31. Bonner-Weir S, Deery D, Leahy JL, Weir GC (1989) Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes 38:49-53
32. Bonner-Weir S, Baxter LA, Schuppin GT, Smith FE (1993) A second pathway for regeneration of adult exocrine and endocrine pancreas. A possible recapitulation of embryonic development. Diabetes 42:1715-1720
33. De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA (2003) Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52:365-371
34. Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276
35. Ilic S, Jovanovic L, Wollitzer AO (2000) Is the paradoxical first trimester drop in insulin requirement due to an increase in C-peptide concentration in pregnant Type I diabetic women? Diabetologia 43:1329-1330
36. Singer F, Horlick M, Poretsky L (1988) Recovery of beta-cell function postpartum in a patient with insulin-dependent diabetes mellitus. N Y State J Med 88:496-498
37. Sinaiko AR, Jacobs DR Jr, Steinberger J et al (2001) Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. J Pediatr 139:700-707
38. Sherry NA, Tsai EB, Herold KC (2005) Natural history of β-cell function in Type 1 diabetes. Diabetes 54 (Suppl 2):S32-S39
39. Caprio S, Boulware D, Tamborlane V (1992) Growth hormone and insulin interactions. Horm Res 38 (Suppl 2):47-49
40. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS (1999) Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 48:989-996
41. Kim SH, Abbasi F, Reaven GM (2004) Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 27:1998-2002
42. Faber OK, Binder C (1977) C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 26:605-610
43. Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264
44. Clarson C, Daneman D, Drash AL, Becker DJ, Ehrlich RM (1987) Residual beta-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve. Diabetes Care 10:33-38
45. Ludvigsson J, Heding LG, Larsson Y, Leander E (1977) C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 66:177-184
46. Wallensteen M, Dahlquist G, Persson B et al (1988) Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 31:664-669
47. Snorgaard O, Lassen LH, Binder C (1992) Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr. Diabetes Care 15:1009-1013
48. Yang L, Zhou ZG, Huang G, Ouyang LL, Li X, Yan X (2005) Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes. World J Gastroenterol 11:2900-2905
49. Faber OK, Binder C (1977) B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment. Diabetologia 13:263-268
50. Madsbad S, McNair P, Faber OK, Binder C, Christiansen C, Transbol I (1980) Beta-cell function and metabolic control in insulin treated diabetics. Acta Endocrinol (Copenh) 93:196-200
51. Lohr M, Kloppel G (1987) Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 30:757-762
52. Daneman D, Clarson C (1987) Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control. Clin Invest Med 10:484-487
53. Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D (1992) Factors predicting course of beta-cell function in IDDM. Diabetes Care 15:997-1001
54. Turner R, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350:1288-1293
55. Landin-Olsson M (2002) Latent autoimmune diabetes in adults. Ann N Y Acad Sci 958:112-116
56. Gottsater A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G (1994) Islet cell antibodies are associated with beta-cell failure also in obese adult onset diabetic patients. Acta Diabetol 31:226-231
57. Hosszufalusi N, Vatay A, Rajczy K et al (2003) Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452-457
58. Eisenbarth GS (1986) Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314:1360-1368
59. Bonner-Weir S (2000) Perspective: postnatal pancreatic beta cell growth. Endocrinology 141:1926-1929